Navigation Links
September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging
Date:9/2/2008

Cataract Removal - New Choices for This Common and Successful Surgery

ROCHESTER, Minn., Sept. 2 /PRNewswire-USNewswire/ -- Here are highlights from the September issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required. Include the following subscription information as your editorial policies permit: Visit http://www.HealthLetter.MayoClinic.com or call toll-free for subscription information, 800-333-9037, extension 9771.

One aspect of aging that's usually fixable is cloudy vision due to cataracts.

In an otherwise healthy eye, cataract removal results in improved vision 95 percent of the time, according to the September issue of Mayo Clinic Health Letter.

Cataracts are common. By age 65, about half of all Americans have developed some degree of lens clouding due to cataracts. Diagnosed during an eye exam, cataracts develop slowly and may not hamper vision much at first. But when cataracts affect the quality of life -- interfering with driving or reading -- it's time to consider surgery, the only treatment.

The most common surgical approach is called phacoemulsification. An ultrasound probe is used to soften and break up the clouded lens, which is suctioned out. Then, the surgeon inserts an artificial flexible lens. The outpatient procedure involves minimal anesthesia and tiny incisions.

The standard lens implant has a single focus point (monofocal), meaning the implanted lens can't adjust for both distant and close-up vision as can a natural lens. When a lens is implanted for distance vision, reading glasses will be needed, and vice versa.

The Food and Drug Administration recently approved a multifocal lens implant that can provide good vision for near and distance vision. However, studies have shown the versatility comes with some tradeoffs in quality of vision. For example, distance vision with a multifocal lens may not be as good as distance vision with a monofocal lens.

Whatever lens is selected, recovery time is generally quick. Mild pain and discomfort diminishes and disappears and vision steadily improves within the first few days. After several weeks of healing, patients can select glasses or contact lenses to fine-tune their vision.

Severe Headache Could Signal Blood Vessel Inflammation

ROCHESTER, Minn. -- Severe and frequent headaches, especially in people who don't typically have headaches, warrant a visit to the doctor.

The headaches could be a symptom of vasculitis -- blood vessel inflammation. Vasculitis is an autoimmune disease, where the body's immune system mistakenly attacks healthy tissue. Depending on the type of vasculitis -- there are more than a dozen -- the disease can disrupt blood circulation and, in some cases, cause death, according to the September issue of Mayo Clinic Health Letter.

In addition to headache, symptoms might include fever, fatigue, weight loss, muscle and joint pain, appetite loss, and numbness or weakness. Often, the exact cause of vasculitis isn't known, although some forms can be linked to infections such as hepatitis B and C, as well as certain medications.

Diagnosis usually involves blood tests and imaging studies of the blood vessels. It also may include a biopsy of an affected blood vessel or tissue.

Treatment depends on the type of vasculitis, its severity and the patient's overall health. The anti-inflammatory properties of corticosteroid medications such as prednisone and methylprednisolone often improve symptoms within days. Immune-suppressing and cytotoxic drugs are used when vasculitis is severe and does not respond to corticosteroids.

Thanks to drug treatments, some types of vasculitis that were once considered fatal can be managed or even go into remission. However, side effects with the medications are a concern. Some medications can increase the risk of serious infections and some cancers. A doctor who has training in this area, often a rheumatologist, can carefully monitor the prescribed medications, their benefits and side effects to best manage the illness.

Dual Energy X-Ray Imaging -- A Better View

ROCHESTER, Minn. -- An emerging imaging technology shows that using two different levels of X-ray energy is better than one, according to the September issue of Mayo Clinic Health Letter.

The new technology, called dual energy X-ray imaging, goes beyond the single perspective image of an X-ray exam or the multiple perspectives of a computerized tomography (CT) scan. Dual energy X-ray imaging can identify the compositions of substances and tissues in the body. Images can be differentiated that would be difficult or impossible to discern in an X-ray or CT scan.

The enhanced image is created using two levels of X-ray energy. After the high-energy reading is cross-referenced with the low-energy reading, an image emerges that is much more precise than standard imaging, which uses a single level of energy.

A handful of medical centers are developing ways to use this technology. For example:

-- Identifying kidney stone compositions -- Unlike a standard CT scan, a dual energy X-ray image can determine if a kidney stone is made of uric acid or if it contains calcium. Uric acid stones can be treated with medication, avoiding surgery.

-- Detecting gout -- A dual energy X-ray image shows the presence and location of gout. Standard X-rays, even combined with a needle biopsy, don't always provide the evidence needed for a clear diagnosis.

Other applications under development are mapping blood vessel flow within organs and visualizing clogged arteries. Although current applications are limited, researchers will likely find more ways to apply dual energy X-ray imaging.

Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. To subscribe, please call 800-333-9037 (toll-free), extension 9771, or visit http://www.HealthLetter.MayoClinic.com.


'/>"/>
SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
2. September is National Pain Awareness Month
3. September is Leukemia, Lymphoma and Myeloma Awareness Month
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
6. Clinical Lab Products Magazine Features Biomoda
7. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
8. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
9. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
10. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
11. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... ITL Limited, ( ASX: ITD ), ... für das zum 31. Dezember 2016 endende Halbjahr ... vorlegen zu können. Eine vollständige Präsentation „Ergebnisse von ... Sie hier . Glanzpunkte ... 2015: 1,04 Millionen USD; +104 %) Gewinn je ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald E. Hawkins, ... the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the ... April 10. Dr. Bell comes to Liberty from the Ohio University Heritage College ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. ... Dyer started as the Chairman of the Management Committee when IFN was originally formed ... the recruitment of investor/owners and development of the business plan. He became the ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... 2017 partnership with The Jensie Gran Fondo of Marin. For the second year ... with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, ...
(Date:2/23/2017)... ... , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS ... longtime supporter of the event. , "We are pleased that KLS Martin is joining ... 2017 ACPA President. "KLS Martin has a long track record of support of the ...
Breaking Medicine News(10 mins):